Mass. biotechs leaping into generic drug market
Biotechnology companies spent years lobbying against generic versions of their expensive cutting-edge therapies, warning that allowing others to copy complicated drugs made from living cells could put patients at risk and undermine innovators . But that was then. Bowing to the inevitability of cheaper competition as federal officials push to contain health care costs, biotechs are now scrambling to secure a piece of the discount market for themselves. And Massachusetts is at the center of the action.